UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

Journal of cystic fibrosis, 2016-06, Vol.15, p.S60-S61

2016

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact

Journal of cystic fibrosis, 2024-01, Vol.23 (1), p.58-64

2024

Link zum Volltext

Verfügbarkeit prüfen

WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species ( BURK ) infection: final results from a randomized, placebo-controlled trial

Journal of cystic fibrosis, 2012-06, Vol.11, p.S11-S11

2012

Link zum Volltext

Verfügbarkeit prüfen

58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection

Journal of cystic fibrosis, 2012-06, Vol.11, p.S71-S71

2012

Link zum Volltext

Verfügbarkeit prüfen

164 Neutrophil elastase-mediated increase in airway temperature during inflammation

Journal of cystic fibrosis, 2013-06, Vol.12, p.S90-S90

2013

Link zum Volltext

Verfügbarkeit prüfen

84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial

Journal of cystic fibrosis, 2011, Vol.10, p.S22-S22

2011

Link zum Volltext

Verfügbarkeit prüfen

Identification of Bordetella spp. in respiratory specimens from individuals with cystic fibrosis

Clinical microbiology and infection, 2008-05, Vol.14 (5), p.504-506

2008

Link zum Volltext

Verfügbarkeit prüfen

Survival After Lung Transplantation of Cystic Fibrosis Patients Infected with Burkholderia cepacia Complex

American journal of transplantation, 2008-05, Vol.8 (5), p.1025-1030

2008

Link zum Volltext

Verfügbarkeit prüfen

P145 Effect of cycled tobramycin on the sputum microbiome in cystic fibrosis

Journal of cystic fibrosis, 2019-06, Vol.18, p.S98-S98

2019

Link zum Volltext

Verfügbarkeit prüfen

Survival of Burkholderia cepacia on environmental surfaces

The Journal of hospital infection, 1996-04, Vol.32 (4), p.267-276

1996

Link zum Volltext

Verfügbarkeit prüfen

Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis?

Transplant infectious disease, 2001-09, Vol.3 (3), p.149-160

LiPuma, J.J.

2001

Link zum Volltext

Verfügbarkeit prüfen

Polyphasic Characterisation of Burkholderia cepacia-Like Isolates Leading to the Emended Description of Burkholderia pyrrocinia

Systematic and applied microbiology, 2004-09, Vol.27 (5), p.517-526

2004

Link zum Volltext

Verfügbarkeit prüfen

Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis

The Lancet (British edition), 1990-11, Vol.336 (8723), p.1094-1096

1990

Link zum Volltext

Verfügbarkeit prüfen

Burkholderia cepacia complex as human pathogens

Journal of nematology, 2003-06, Vol.35 (2), p.212-217

LiPuma, J.J

2003

Link zum Volltext

Verfügbarkeit prüfen

Survival following lung transplantation (LT) of cystic fibrosis (CF) patients infected with burkholderia cepacia complex (BCC)

The Journal of heart and lung transplantation, 2004-02, Vol.23 (2), p.S73-S73

2004

Link zum Volltext

Verfügbarkeit prüfen

Burkholderia cepacia et agriculture biologique

Revue française des laboratoires, 2002-12, Vol.2002 (348), p.17-17

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact

WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species ( BURK ) infection: final results from a randomized, placebo-controlled trial

58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection

164 Neutrophil elastase-mediated increase in airway temperature during inflammation

84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial

Identification of Bordetella spp. in respiratory specimens from individuals with cystic fibrosis

Survival After Lung Transplantation of Cystic Fibrosis Patients Infected with Burkholderia cepacia Complex

P145 Effect of cycled tobramycin on the sputum microbiome in cystic fibrosis

Survival of Burkholderia cepacia on environmental surfaces

Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis?

Polyphasic Characterisation of Burkholderia cepacia-Like Isolates Leading to the Emended Description of Burkholderia pyrrocinia

Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis

Burkholderia cepacia complex as human pathogens

Survival following lung transplantation (LT) of cystic fibrosis (CF) patients infected with burkholderia cepacia complex (BCC)

Burkholderia cepacia et agriculture biologique

Suchergebnisse filtern